Merck Financial News

01.09 / 20:53

COST Manufacturing Merck Patrick J&J cover Novartis sues US government over Medicare drug price regulation

By Patrick Wingrove

29.08 / 12:21

BLOCK Manufacturing Merck Pfizer Southern Factbox-Court challenges to Medicare drug price negotiation plan

(Reuters) — The U.S. government on Tuesday selected the first 10 drugs, including the big-selling blood thinner Eliquis from Bristol Myers (NYSE:BMY) Squibb and Pfizer (NYSE:PFE), that will be subject to the first-ever Medicare price negotiations, part of President Joe Biden’s Inflation Reduction Act (IRA) that drugmakers and industry groups have challenged in court.

29.08 / 12:13

COST UPS Manufacturing Merck Pfizer Patrick cover Explainer Explainer-Why the US is negotiating the price of 10 drugs

By Patrick Wingrove

29.08 / 10:43

COST Merck Pfizer Patrick AbbVie cover US to name first 10 drugs for Medicare price negotiation

By Patrick Wingrove

25.08 / 13:42

Target BLOCK Reuters Merck AstraZeneca AstraZeneca sues US over Medicare drug price negotiation plans

(Reuters) -AstraZeneca said on Friday it has sued the U.S. government to block parts of a program that gives the Medicare health insurance plan the power to negotiate lower drug prices.

21.08 / 17:23

COST BLOCK Merck country Boehringer latest to sue US over drug price negotiation plan

By Brendan Pierson

01.08 / 14:03

NASDAQ DOW Merck Pfizer stage U.S. stocks were wobbling as investors take in megacap earnings

Investing.com — U.S. stocks were wobbling as investors digested a slew of megacap earnings reports and awaited economic data that could set the stage for the Federal Reserve’s next meeting.

01.08 / 13:25

Manufacturing Caterpillar Merck Pfizer show open Wall St set to open lower ahead of manufacturing, jobs data

By Johann M Cherian and Bansari Mayur Kamdar

01.08 / 13:05

Amazon Platform Caterpillar Merck Pfizer JetBlue fall Caterpillar, Merck rise premarket; Pfizer, JetBlue and ZoomInfo fall

Investing.com — U.S. futures edged lower Tuesday, with investors digesting more corporate earnings as well as key job openings data.

01.08 / 13:05

Reuters Platform Caterpillar Merck Starbucks Meta Platforms social chatbot Busy earnings day, Meta reportedly prepares AI chatbot - what's moving markets

Investing.com — Investors are preparing to sift through a deluge of corporate results on Tuesday from big-name brands like Merck, Starbucks and Caterpillar . Meanwhile, Facebook-owner Meta Platforms is reportedly gearing up to launch a new artificial intelligence chatbot that can take on the personas of different characters. Elsewhere, a bright pulsating sign on the roof of the headquarters of Elon Musk's newly-renamed social media group X is taken down after sparking controversy with local residents.

01.08 / 12:27

Target CEO Gap Caterpillar Merck Pfizer Incyte Stocks making the biggest moves premarket: Uber, Gap, Caterpillar & more

Check out the companies making headlines before the bell on Tuesday.

28.07 / 15:11

Lowe's Merck Moderna Pfizer CVS Vertex Gilead week Pro Research of the Week: Is Pfizer the Best Bet Among Big Pharma Stocks?

Earnings season is in full swing, and next week, we've got our sights set on the healthcare sector, specifically pharmaceutical and biotechnology companies, as they get ready to reveal their quarterly results.

26.07 / 11:25

Merck Moderna Moderna/Merck begin late-stage study of mRNA cancer vaccine

(Reuters) — Moderna (NASDAQ:MRNA) and drugmaker Merck have started a late-stage study to evaluate their experimental mRNA-based cancer vaccine in combination with cancer therapy Keytruda, the companies said on Wednesday.

18.07 / 16:17

BLOCK Manufacturing Merck J&J J&J sues US govt to halt Medicare drug price negotiation plans

(Reuters) — Johnson & Johnson (NYSE:JNJ) sued the U.S. government on Tuesday, becoming the latest drugmaker seeking to block enforcement of a program that gives Medicare the power to negotiate drug prices.

11.07 / 04:15

COST Lowe's Digital SUN Merck Q1 results preview: Here's why pharma companies are expected to show improvement

Sun Pharmaceutical Industries: The brokerage anticipates that domestic formulations will remain weak (+8% YoY) due to the impact of the NPPA, the patent expiration of two significant goods licenced from Merck, and the seasonal weakness for acute medications. "We expect overall EBITDA margins at about 24% (-100bps YoY) impacted partly by Halol remediation cost, consolidation of Concert’s cost and cost inflation. US revenue (~USD440mn), +2% QoQ in cc mainly on account uptick in specialty business and gRevlimid (+4% QoQ excluding licensing income in Q4).

06.07 / 22:05

Target Merck Pfizer Roivant Sciences $7 billion bowel drug draws major pharma interest

Pharmaceutical company Roivant Sciences Ltd (NASDAQ:ROIV) has garnered interest from major pharmaceutical companies for its treatment of inflammatory bowel disease, estimated to be valued at over $7 billion, as reported by Bloomberg, which cited sources familiar with the matter.

04.07 / 09:07

Merck Strategy Cardiovascular Merck India appoints Pratima Reddy as country speaker

Science and technology company Merck has announced the appointment of Pratima Reddy as country speaker for India, said a statement issued today. Reddy takes on this role in addition to leading healthcare strategy and operations in India as GM and managing director of Merck Specialities India.

17.04 / 18:53